Healthcare / Medical DevicesNasdaqCM
$4.30
-0.08 (-1.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-39.5M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$132M
P/E
N/A
•EV/EBITDA
N/A
•ROE
291.8%
↑Gross Margin
82.1%
↑Debt/Equity
-2.77
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
+86.0%
FCF CAGR
—
FCF margin
-46.0%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $71.6M · net income $-48.6M · FCF $-32.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $71.6M | $71.6M | $64.3M | $50.1M | $34.4M | — | $14.3M | $5.5M | $929000.00 |
| Net Income | $-48.6M | $-48.6M | $-61.8M | $-35.4M | $-26.7M | — | $-42.0M | $-25.1M | $-12.7M |
| EBITDA | $-41.2M | $-41.2M | $-55.3M | $-33.5M | $-26.0M | — | $-42.2M | $-25.3M | $-13.7M |
| EPS | -1.74 | -1.74 | -2.39 | -1.40 | -1.07 | — | 2.07 | 1.56 | 1.37 |
| Gross Margin | 82.1% | 82.1% | 85.8% | 84.5% | 82.4% | — | 79.2% | 76.8% | 41.2% |
| Operating Margin | -59.4% | -59.4% | -88.1% | -85.1% | -79.9% | — | -299.2% | -466.4% | -1489.9% |
| Net Margin | -67.8% | -67.8% | -96.3% | -70.6% | -77.5% | — | -294.7% | -458.6% | -1370.8% |
| Balance Sheet | |||||||||
| Debt/Equity | -2.77 | -2.77 | 10.22 | 0.86 | 0.01 | — | — | — | — |
| Current Ratio | 0.47 | 0.47 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-32.9M | $-32.9M | $-58.3M | $-39.5M | $-19.6M | — | $-23.3M | $-20.3M | $-13.3M |
| Returns | |||||||||
| ROE | 291.8% | 291.8% | -1374.6% | -72.1% | -31.5% | — | -58.1% | -120.5% | -90.8% |
| Valuation | |||||||||
| P/B | — | — | 76.17 | 6.49 | 2.02 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 11.5% | 11.5% | 28.1% | 45.7% | — | — | 160.6% | 489.2% | — |
| EPS Growth | 27.2% | 27.2% | -70.7% | -30.8% | — | — | 32.7% | 13.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.39 → -1.74
Residual
-28.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.